Literature DB >> 27824286

The assessment of Hantaan virus-specific antibody responses after the immunization program for hemorrhagic fever with renal syndrome in northwest China.

Zhuo Li1,2, Hanyu Zeng1, Ying Wang1, Yusi Zhang1, Linfeng Cheng3, Fanglin Zhang3, Yingfeng Lei3, Boquan Jin1, Ying Ma1, Lihua Chen1.   

Abstract

Xianyang city is one of the main hemorrhagic fever with renal syndrome (HFRS) epidemic areas in northwest China. Although the HFRS immunity program has been provided in this city, HFRS is still occurred every year. In order to implement the vaccination program effectively and to control HFRS, the analysis of antibody responses specific to Hantaan virus (HTNV) in individuals after vaccination is essential. In this study, a total of 100 subjects were divided into 5 groups: unvaccinated, 1, 3, 29 and 33 months after boost vaccination. The levels and the positive rates of HTNV-NP-specific IgM and IgG antibodies as well as HTNV neutralizing antibodies were significantly increased in the serum of the vaccinated individuals. The positive rates and levels of HTNV-NP-specific IgG and HTNV neutralizing antibody reached their highest values at 3 months respectively and could be sustained up to 33 months after vaccination. Moreover, the titres of HTNV-NP-specific IgM or IgG antibody and the titres of HTNV neutralizing antibody at 1 month after vaccination have a positive correlation. The level of HTNV-NP-specific IgG antibody was much higher than that of HTNV-NP-specific IgM antibody or HTNV neutralizing antibody. In addition, the strongest responses of antibody-secreting cells were observed at 3 months after vaccination, which was consistent with the serum results. Therefore, the HFRS immunization program is effective to induce humoral immunity in the population of northwest China.

Entities:  

Keywords:  Hantaan virus; antibody response; hemorrhagic fever with renal syndrome; humoral immunity; vaccination

Mesh:

Substances:

Year:  2016        PMID: 27824286      PMCID: PMC5404621          DOI: 10.1080/21645515.2016.1253645

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  19 in total

1.  The impact of the vaccination program for hemorrhagic fever with renal syndrome in Hu County, China.

Authors:  Dan Xiao; Kejian Wu; Xin Tan; Tiecheng Yan; Haitao Li; Yongping Yan
Journal:  Vaccine       Date:  2013-11-16       Impact factor: 3.641

Review 2.  Hantaviruses: genome structure, expression and evolution.

Authors:  A Plyusnin; O Vapalahti; A Vaheri
Journal:  J Gen Virol       Date:  1996-11       Impact factor: 3.891

3.  [The current epidemic situation and surveillance regarding hemorrhagic fever with renal syndrome in China, 2010].

Authors:  Li-Yong Huang; Hang Zhou; Wen-Wu Yin; Qin Wang; Hui Sun; Fan Ding; Teng-Fei Man; Qun Li; Zi-Jian Feng
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2012-07

4.  Construction and evaluation of DNA vaccine encoding Hantavirus glycoprotein N-terminal fused with lysosome-associated membrane protein.

Authors:  Dong-Bo Jiang; Yuan-Jie Sun; Lin-Feng Cheng; Ge-Fei Zhang; Chen Dong; Bo-Quan Jin; Chao-Jun Song; Ying Ma; Fang-Lin Zhang; Kun Yang
Journal:  Vaccine       Date:  2015-05-28       Impact factor: 3.641

Review 5.  Dobrava-Belgrade virus: phylogeny, epidemiology, disease.

Authors:  Anna Papa
Journal:  Antiviral Res       Date:  2012-05-30       Impact factor: 5.970

Review 6.  New ecological aspects of hantavirus infection: a change of a paradigm and a challenge of prevention--a review.

Authors:  Martin Zeier; Michaela Handermann; Udo Bahr; Baldur Rensch; Sandra Müller; Roland Kehm; Walter Muranyi; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

7.  Detection of phylogenetically distinct Puumala-like viruses from red-grey vole Clethrionomys rufocanus in China.

Authors:  Yong-Zhen Zhang; Yang Zou; Yan-Zhen Yan; Guang-Wei Hu; Lai-Shun Yao; Zhan-Sheng Du; Long-Zhe Jin; Yao-Yuan Liu; Ming-Hui Li; Hua-Xin Chen; Zhen F Fu
Journal:  J Med Virol       Date:  2007-08       Impact factor: 2.327

8.  Changes in age distribution of hemorrhagic fever with renal syndrome: an implication of China's expanded program of immunization.

Authors:  Xiaozhou He; Shiwen Wang; Xiaoxia Huang; Xiaofang Wang
Journal:  BMC Public Health       Date:  2013-04-26       Impact factor: 3.295

9.  Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.

Authors:  Amy Leval; Eva Herweijer; Alexander Ploner; Sandra Eloranta; Julia Fridman Simard; Joakim Dillner; Cecilia Young; Eva Netterlid; Pär Sparén; Lisen Arnheim-Dahlström
Journal:  J Natl Cancer Inst       Date:  2013-03-13       Impact factor: 13.506

Review 10.  Vaccines for the 21st century.

Authors:  Isabel Delany; Rino Rappuoli; Ennio De Gregorio
Journal:  EMBO Mol Med       Date:  2014-04-06       Impact factor: 12.137

View more
  11 in total

Review 1.  Hantavirus Infections-Treatment and Prevention.

Authors:  Kalpa Dheerasekara; Saranga Sumathipala; Rohitha Muthugala
Journal:  Curr Treat Options Infect Dis       Date:  2020-10-29

Review 2.  Progress on the Prevention and Treatment of Hantavirus Disease.

Authors:  Rebecca L Brocato; Jay W Hooper
Journal:  Viruses       Date:  2019-07-04       Impact factor: 5.048

3.  Design and synthesis of HLA-A*02-restricted Hantaan virus multiple-antigenic peptide for CD8+ T cells.

Authors:  Yan Ma; Kang Tang; Yusi Zhang; Chunmei Zhang; Yun Zhang; Boquan Jin; Ying Ma
Journal:  Virol J       Date:  2020-01-31       Impact factor: 4.099

4.  Coumarin Derivative N6 as a Novel anti-hantavirus Infection Agent Targeting AKT.

Authors:  Zhoupeng Li; Fang Wang; Yongsheng Liu; Dongshen Zhai; Xiaoxiao Zhang; Qikang Ying; Min Jia; Xiaoyan Xue; Jingru Meng; Jing Li; Xingan Wu; Mingkai Li
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

5.  The Clinical Characteristics and Outcomes of Hemorrhagic Fever With Renal Syndrome in Pregnancy.

Authors:  Danfeng Ren; Shan Fu; Taotao Yan; Tianzhi Ni; Ze Zhang; Mengmeng Zhang; Jingwen Zhou; Nan Yang; Yuan Yang; Yingli He; Tianyan Chen; Yingren Zhao; Jinfeng Liu
Journal:  Front Med (Lausanne)       Date:  2022-02-21

6.  UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments.

Authors:  Rob J Noad; Karl Simpson; Anthony R Fooks; Roger Hewson; Sarah C Gilbert; Mark P Stevens; Margaret J Hosie; Joann Prior; Anna M Kinsey; Gary Entrican; Andrew Simpson; Christopher J M Whitty; Miles W Carroll
Journal:  Vaccine       Date:  2019-09-12       Impact factor: 3.641

Review 7.  Vaccines and Therapeutics Against Hantaviruses.

Authors:  Rongrong Liu; Hongwei Ma; Jiayi Shu; Qiang Zhang; Mingwei Han; Ziyu Liu; Xia Jin; Fanglin Zhang; Xingan Wu
Journal:  Front Microbiol       Date:  2020-01-30       Impact factor: 5.640

8.  Integrative Analysis of HTNV Glycoprotein Derived MHC II Epitopes by In Silico Prediction and Experimental Validation.

Authors:  Hao Sun; Zhenhua Lu; Guoyun Xuan; Ning Liu; Tianhu Wang; Yang Liu; Mingfu Lan; Jiahao Xu; Yuancai Feng; Shuang Xu; Yuchen Lu; Baozeng Sun; Jinpeng Zhang; Xiyang Zhang; Yuanjie Sun; Shuya Yang; Yun Zhang; Yusi Zhang; Linfeng Cheng; Dongbo Jiang; Kun Yang
Journal:  Front Cell Infect Microbiol       Date:  2021-07-19       Impact factor: 5.293

9.  Immunogenic Properties of MVs Containing Structural Hantaviral Proteins: An Original Study.

Authors:  Layaly Shkair; Ekaterina Evgenevna Garanina; Ekaterina Vladimirovna Martynova; Alena Igorevna Kolesnikova; Svetlana Sergeevna Arkhipova; Angelina Andreevna Titova; Albert Anatolevich Rizvanov; Svetlana Francevna Khaiboullina
Journal:  Pharmaceutics       Date:  2022-01-01       Impact factor: 6.321

Review 10.  Hantavirus Induced Kidney Disease.

Authors:  Sheema Mir
Journal:  Front Med (Lausanne)       Date:  2022-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.